Literature DB >> 16200151

Ximelagatran (Exanta): alternative to warfarin?

Christy Vaughan1.   

Abstract

Entities:  

Year:  2005        PMID： 16200151      PMCID： PMC1200703          DOI： 10.1080/08998280.2005.11928037

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  12 in total

1.  Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Authors:  Karin Wåhlander; Leif Lapidus; Carl-Gustav Olsson; Anneli Thuresson; Ulf G Eriksson; Göran Larson; Henry Eriksson
Journal:  Thromb Res       Date:  2002-08-15       Impact factor: 3.944

2.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

Authors:  D Gustafsson; J Nyström; S Carlsson; U Bredberg; U Eriksson; E Gyzander; M Elg; T Antonsson; K Hoffmann; A Ungell; H Sörensen; S Någård; A Abrahamsson; R Bylund
Journal:  Thromb Res       Date:  2001-02-01       Impact factor: 3.944

3.  Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

Authors:  Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Patrick Mouret; Nadia Rosencher; Christina Eskilson; Ingela Nylander; Lars Frison; Mats Ogren
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

4.  Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.

Authors:  Palle Petersen; Margaretha Grind; John Adler
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

5.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Authors:  Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-27       Impact factor: 2.953

Review 6.  The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.

Authors:  David Gustafsson; Margareta Elg
Journal:  Thromb Res       Date:  2003-07-15       Impact factor: 3.944

7.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Authors:  Sam Schulman; Karin Wåhlander; Torbjörn Lundström; Solveig Billing Clason; Henry Eriksson
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

8.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Authors:  Charles W Francis; Scott D Berkowitz; Philip C Comp; Jay R Lieberman; Jeffrey S Ginsberg; Guy Paiement; Gary R Peters; Anne W Roth; Jennifer McElhattan; Clifford W Colwell
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

9.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

10.  Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

Authors:  C W Colwell; S D Berkowitz; B L Davidson; P A Lotke; J S Ginsberg; J R Lieberman; J Neubauer; J L McElhattan; G R Peters; C W Francis
Journal:  J Thromb Haemost       Date:  2003-10       Impact factor: 5.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.